Citation Tools
PDFRegular and Young Investigator Award Abstracts
Combination Immunotherapies
801 Risk-benefit ratio in immunotherapy (IO) with or without chemotherapy (CT) according to PD-L1 expression: a model-based approach to inform treatment decisions in metastatic non-small cell lung cancer
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 801 Risk-benefit ratio in immunotherapy (IO) with or without chemotherapy (CT) according to PD-L1 expression: a model-based approach to inform treatment decisions in metastatic non-small cell lung cancer